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Background: The NHS is responsible for approximately 30% of all public sector carbon emissions. The
Climate Change Act 2008 introduced legally binding targets to cut emissions of greenhouse gases (GHGs)
by at least 80% of the 1990 baseline by 2050. This paper seeks to examine two different strategies for the
treatment of gastro-oesophageal reﬂux disease and their modelled costs and carbon emissions.
Methods: This study uses data from the costs of care of patients in the REFLUX study and NHS England
Carbon Emissions Carbon Footprinting Report to model the carbon emissions associated with medical
and surgical treatment of gastro-oesophageal reﬂux disease. The main outcome measures are modelled
ﬁnancial costs and carbon emissions for medical and surgical treatment pathways.
Results: There is a high initial cost (ﬁnancially and carbon emissions) for surgery, however subsequent year-
on-year ﬁnancial spend and carbon emissions are lower in patients who have had surgical treatment such
that the total modelled ﬁnancial cost of surgery is lower in the 14th year and carbon emissions are lower in
the 9thyear. Themodel is sensitive to changes in the efﬁciencyof pharmaceutical procurement and surgical
failure rate.
Conclusions: The model has demonstrated that in cases of equivalent clinical beneﬁt one pathway may be
preferred on the basis of other factors including carbon emissions.
 2010 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Summary
Previous studies have demonstrated a high-rate of subsequent
failure of reﬂux control and this combined with the cost of anti-
reﬂux surgery have resulted in medical therapy dominating
surgical reﬂux control on a cost-basis. Two recent multicentre
studies (the UK REFLUX trial1 and European LOTUS trial2) of anti-
reﬂux surgery versus medical therapy have demonstrated similar
or superior efﬁcacy of laparoscopic fundoplication to medical
treatment in the short term (up to 3 years).
The improved outcome of the surgical arms of the recent trials
and UK National Health Service commitment to reduce its carbon
emissions3 bring to light the question: if clinical outcomes are
comparable then will the carbon footprint of different treatment
pathways inﬂuence patients’, clinicians’ and institutions’ choices in
deciding which treatment pathway to choose.
A Health Technology Assessment paper has looked at the
comparative costs of the patients randomised to medical andUniversity College London,
3 2PF, UK. Tel.: þ44 (0) 20
ciates Ltd. Published by Elsevier Ltsurgical therapy4 and this data can be extrapolated to examine the
carbon footprint of the surgical and medical treatment arms.2. Introduction
This paper examines the difference in carbon footprint between
the surgical and medical treatment of gastro-oesophageal reﬂux.
The analysis is undertaken using a top-down model of carbon
emissions using data activity from the REFLUX trial HTA paper4 and
from the NHS Carbon Emissions Modelling5 (which combines data
from the Ofﬁce of National Statistics (procurement data), National
Travel Survey (travel data) and Multi-Regional Input-Output data
(buildings use data).
3. Methods
The estimated carbon footprint is compared between two groups: 1 those who
underwent antireﬂux surgery (n ¼ 154) and 2 those who had medical control of
reﬂux (n ¼ 164). The method used for accounting for the carbon cost of each indi-
vidual component of care and CO2 emission per unit is given in Table 1.
Visits to and from the family practitioner were similar between the surgical and
medical groups (46 and 45%) and data on the carbon emissions from primary care
are sparse. Subsequently, these have been excluded from the model.
The model has assumed that only patients who are considered for surgery will
undergo pre-operative evaluationwith endoscopy, pHometry andmanometry and ind. All rights reserved.
Table 1
Method for carbon accounting.
Component of Care Financial Unit Cost (£) Method of Carbon Accounting Carbon Unit Emissions
(KgCO2 per unit)
Endoscopy 172 NHS Carbon Emissions Modelling overall carbon intensity 91.16
pH tests 84 NHS Carbon Emissions Modelling overall carbon intensity 44.52
Manometry 61 NHS Carbon Emissions Modelling overall carbon intensity 32.33
Operation time 4 NHS Carbon Emissions Modelling overall carbon intensity 2.12
Consumables 825 NHS Carbon Emissions Modelling medical instruments
carbon intensity
379.5
Inpatient care/day 213 NHS Carbon Emissions Modelling overall carbon intensity 112.89
ICU 1470 NHS Carbon Emissions Modelling overall carbon intensity 779.1
HDU 628 NHS Carbon Emissions Modelling overall carbon intensity 332.84
Visit to GP 24 Excluded
Visit from GP 69 Excluded
Outpatient appointment 142 NHS Carbon Emissions Modelling overall carbon intensity 75.26
Day case 460 NHS Carbon Emissions Modelling overall carbon intensity 243.8
Inpatient care 1378 NHS Carbon Emissions Modelling overall carbon intensity 730.34
Non-randomised surgery 2596 NHS Carbon Emissions Modelling overall carbon intensity 1375.88
Medication costs 1 NHS Carbon Emissions Modelling pharmaceuticals
carbon intensity
0.56
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sions in the surgical arm. The model has assumed that the medication usage will
remain constant for patients in both arms following the decision to embark on
medical or surgical therapy, with no changes subsequently (patients in the medical
armrequiring ameanof £179per annumtobe spentonmedication and in the surgical
arm £55per annum,which includes those requiring additionalmedication for control
of reﬂux). The model assumes that 1 in 20 medical patients will cross-over to the
surgical arm (at a higher cost than those initially treated with surgery as per the HTA
paper’s costings, but accounting for less than the cost of oneyear ofmedication for the
wholemedical cohort). Therewere small costs factored in to cover patients requiring
further procedures or admissions within the ﬁrst year, but these were not continued
for subsequent years. Subsequently, after the ﬁrst year, ongoing treatment costs were
modelled as continued medication use in both groups only.
The outcome is the ﬁnancial cost and estimated carbon emission for each group
over time.4. Results
The initial cost modelling demonstrated that the overall cost of
surgery (excluding medications and GP visits) was £2039 and for
medical treatment was £309 (which includes the cost of 5% of
patients subsequently undergoing antireﬂux surgery). The break-
down of these costs is presented in Table 2. The ongoing costs
modelled are those of continued medication use. This estimates
that the mean cost of medication use was £179 per annum in the
medical arm and £55 per annum in the surgical arm. This equates to
ongoing emissions of 100 Kg CO2 per annum in the medical armTable 2
Financial and carbon costs of treatment arms.
Component of Care Medical Use
(units)
Medical ﬁnancial
spend (£)
M
em
(k
Endoscopy 0 0
pH tests 0 0
Manometry 0 0
Operation time 0 0
Consumables 0 0
Inpatient care/day 0 0
ICU 0 0
HDU 0 0
Visit to GP 1.21 29.04
Visit from GP 0.01 0.69
Outpatient appointment 0.3 42.6 2
Day case 0.17 78.2 4
Inpatient care 0.02 27.56 1
Non-randomised surgery 0.05 129.8 6
Medication costs 179 179 10and 30 Kg CO2 per annum in the surgical arm. If the assumptions
hold then this will result in antireﬂux surgery being cost-efﬁcient
in the 14th year post-operatively and carbon-efﬁcient in the 9th
post-operative year (Fig. 1).5. Discussion
The treatment of gastro-oesophageal reﬂux has been revolu-
tionized by technological advances in pharmacological and surgical
technologies. The proton pump inhibitors provide excellent
suppression of stomach secretions with reductions in the volume
and acidity the reﬂuxate. In England there were 36 million
community prescriptions for proton pump inhibitors in 2009, at
a cost of £187 million (representing 4.1% of NHS drug prescriptions
and 2.2% of drug spend).6 These ﬁgures do not cover patients who
self-medicated or those taking other classes of drugs to suppress
gastric acidity and reﬂux, however some patients (less than one
third) will take thesemedications for indications other than reﬂux.7
Ten percent of the population in western countries may experience
daily reﬂux symptoms and larger numbers experience symptoms
less frequently.8
Hospital Episode Statistics Data indicate that 3896 primary
antireﬂux operations were undertaken in England in the year
2008e2009 (and 310 revision operations).9 The average age ofedical CO2
issions
g Co2)
Surgical Use
(units)
Surgical ﬁnancial
spend (£)
Surgical CO2
emissions
(Kg CO2)
0 0.59 101.48 53.7844
0 0.47 39.48 20.9244
0 0.45 27.45 14.5485
0 77.34 309.36 163.9608
0 1 825 379.5
0 1.91 406.83 215.6199
0 0 0 0
0 0.03 18.84 9.9852
0 1.18 28.32 0
0 0.01 0.69 0
2.578 0.46 65.32 34.6196
1.446 0.38 174.8 92.644
4.6068 0.03 41.34 21.9102
8.794 0 0 0
0.24 55 55 30.8
Fig. 1. Financial cost and carbon emissions over time.
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tancy of 42.5 further years and males have 39.1 years).10 Laparo-
scopic surgery provides a robust control of reﬂux with minimal
operative morbidity, but some post-treatment symptoms are
common such as bloating and diarrhoea.8 The most recent multi-
centre studies of laparoscopic antireﬂux surgery compared to
medical treatment have demonstrated similar efﬁcacy of the
different strategies.2,4 Under these circumstances, other factors
come in to decisionmaking, whichmay include the carbon footprint
of different strategies.
There are several ﬂaws in the approach to this study.
The data used were taken from a large multicentre cohort from
the UK. As such, the assumptions made in linking the ﬁnancial cost
to NHS carbon emissions are applicable, however these data from
the REFLUX study4 were not intended for this purpose and
a signiﬁcant assumption is that the ﬁrst year data may be extrap-
olated into the future with regard to medication usage or failure/
complications of the surgery. The pharmaceutical and instrument
manufacturers may be able to improve the efﬁciency of their
manufacturing processes and supply chain (and the overall carbon
intensity (KgCO2/£ spent) has been steadily falling since 19925),
which will have a signiﬁcant impact on the carbon emissions as will
small variation in the number of patients in the surgical arm who
continue to take antireﬂux medication. The model does not take
into account differences in carbon intensity for different origins of
manufacture (for example procurement from European OECD
countries have one sixth the carbon intensity of non-European
countries).
The model has assumed that patients in the medical treatment
arm did not undergo endoscopic and physiological assessment,
which is likely to underestimate the use of upper alimentary
endoscopy. Similarly, not all surgical patients had a full set of
investigations prior to antireﬂux surgery, which would not be
representative of all surgeons’ practice.
The continued treatment modelling is also weakened by the
absence of factoring in costs of further follow-up (either at the
hospital or in primary care), the need to attend for ongoing
prescriptions and the cost of travel to these appointments and to
collect the medications.
The approach taken is top-down approach predominantly,
where carbon costs are derived from ﬁnancial costs and therefore
the results for carbon and cost are similar. A more robust meth-
odology would be to undertake a bottom-up approach where
travel, pharmaceutical and instrument spend could be evaluatedmore accurately, rather than using the overall NHS ﬁgure for carbon
intensity to model the majority of the costs of the surgical arm.
The ideal approach would be to know the carbon footprint of
each individual medical instrument, medication, suture etc used,
however these data are not yet known for the majority of items and
so even this approach would need to use estimates of the carbon
footprint of each item based upon DEFRA ﬁgures for carbon
intensity.5
Despite the many methodological ﬂaws, this paper does raise
questions in the need to start to examine the carbon cost of
treatment with the need for early prompt action to mitigate
climate change11 and government’s Carbon Reduction Strategy
commitments.
Further work should start to develop standardised methodolo-
gies, which will allow accurate comparison of care pathways to
each other and over time.
For control of reﬂux, if the failure rate remains low and life
expectancy remains around 40 years, antireﬂux surgery offers
options for reduction in carbon footprint and costs over current
best medical therapy.
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